Depressive Episode Incidence in Patients With Chronic Hepatitis C Treated With Pegylated Interferon and Ribavirin

Abstract

-Background -The effectiveness of antiviral therapy with pegylated interferon and ribavirin for chronic hepatitis C is far from ideal and presents several adverse events. Among such events, there is the depressive episode that can even lead to treatment discontinuity. Objective -Analyze the incidence of depressive episodes in patients with chronic hepatitis C treated with pegylated interferon (IFN-PEG) and ribavirin, as well as the possible factors associated with its occurrence and its impact on patients' sustained virological response. Methods -People with chronic hepatitis C undergoing antiviral therapy were interviewed at the baseline, at the 4th, 12th, 24th and 48th treatment weeks and 4 weeks after the end of it, using the HADS scale for tracking the depressive episode.Patients with HADS ≥9 were subjected to Beck Depression Inventory (BDI-II) to grade the episode. Clinical, sociodemographic, laboratorial and histological variables were obtained to identify factors related to the onset of depression. The sustained virological response rate (negative HCV-RNA 6 months after end of therapy) was compared among patients with and without depressive symptoms. Results -The study comprised 32 patients, most men (59%) with mean age of 54±11.13 years old. Genotype non-1 was prevalent (56%) and 81% of the patients were non-cirrhotic. The depressive episode was diagnosed in 25% of the patients and the peak incidence was found in the 12th treatment week. The depressive episode was moderate in 87% of the patients and only one patient abandoned the treatment. None of the analyzed factors was associated with depressive episode onset. A trend was observed in female patients (P=0.08). The sustained virological response rate was of 75% and 67% in patients with and without depressive episode, respectively (P=0.66). Conclusion -The incidence of depressive episodes in patients with chronic hepatitis C undergoing antiviral therapy was of 25% and the 12th treatment week was the most critical one. The presence of depressive episode did not affect the sustained virological response rate. HEADINGS -Depression. Chronic hepatitis C. Interferon-alpha.

Quality of Life and Work Ability among Healthcare Personnel with Chronic Viral Hepatitis. Evaluation of the Inpatient Rehabilitation Program of the Wartenberg Clinic

“…In the past, adverse events would frequently result in medically-induced abandonment of treatment. Pronounced side effects such as depression and long treatment times, sometimes with low success rates, had a negative impact on therapy compliance among patients, sometimes resulting in severe progression of the disease [23,24,25,26]. In the subgroup of the study of participants who had received interferon treatment, around one-third suffered from persistent side effects.…”

A Survey on the Prevalence of Depression in Blood Donors with Hepatitis C in Shiraz

“…The detection of depression in HCV patient is essential because undetected depression may decrease adherence to therapy, decline drug efficacy, jeopardize treatment continuity, decrease quality of life, and reduce the chances of eradicating the virus (14, 22). In addition, another previous study showed patients who suffer from both depression and comorbid medical illness had approximately twice impairments in social functioning compare to medical illness or depression alone (13).…”

Inhibition of emotional needs and emotional wellbeing predict disease progression of chronic hepatitis C patients: an 8-year prospective study

“…The adjustment for this factor, together with the above mentioned “disadvantageous” condition for SVR, might have masked the true effect of SVR in this particular cohort. Another issue to be discussed about antiviral therapy is IFN’s potential side effects on psychological status, including induction or progression of depression [ 53 , 54 ]. It is possible that the IFN therapy might change the psychosocial status of some patients, and psychological and behavioral aspects as evaluated via the SI and FACIT scales might have been affected by antiviral therapy with IFN.…”